Mural Oncology PLCNASDAQ:MURA
- LAST PRICE3.5800
- TODAY'S CHANGE (%)0.0500 (1.4164%)
- Bid / Lots3.4200/ 1
- Ask / Lots3.8500/ 1
- Open / Previous Close3.5400 / 3.5300
- Day Range
- 52 Week Range
- Volume96,328
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MURA |
|---|---|---|
| 09:32 ET | 221 | 3.54 |
| 09:50 ET | 100 | 3.54 |
| 09:52 ET | 100 | 3.57 |
| 09:54 ET | 228 | 3.585 |
| 09:56 ET | 200 | 3.62 |
| 09:59 ET | 100 | 3.6 |
| 10:01 ET | 100 | 3.6 |
| 10:03 ET | 100 | 3.6 |
| 10:06 ET | 200 | 3.6 |
| 10:10 ET | 2463 | 3.61 |
| 10:12 ET | 100 | 3.62 |
| 10:14 ET | 100 | 3.62 |
| 10:15 ET | 363 | 3.63 |
| 10:17 ET | 3065 | 3.64 |
| 10:19 ET | 2130 | 3.59 |
| 10:26 ET | 200 | 3.6 |
| 10:30 ET | 100 | 3.61 |
| 10:32 ET | 439 | 3.61 |
| 10:33 ET | 100 | 3.63 |
| 10:37 ET | 200 | 3.61 |
| 10:39 ET | 131 | 3.62 |
| 10:42 ET | 424 | 3.63 |
| 10:44 ET | 100 | 3.62 |
| 10:46 ET | 113 | 3.62 |
| 10:57 ET | 100 | 3.6 |
| 11:06 ET | 100 | 3.59 |
| 11:11 ET | 200 | 3.595 |
| 11:13 ET | 161 | 3.58 |
| 11:15 ET | 154 | 3.58 |
| 11:18 ET | 2611 | 3.55 |
| 11:20 ET | 400 | 3.53 |
| 11:22 ET | 1538 | 3.52 |
| 11:24 ET | 800 | 3.5 |
| 11:26 ET | 500 | 3.5001 |
| 11:27 ET | 300 | 3.5 |
| 11:31 ET | 300 | 3.51 |
| 11:33 ET | 200 | 3.51 |
| 11:36 ET | 6540 | 3.48 |
| 11:38 ET | 2333 | 3.5 |
| 11:40 ET | 3211 | 3.5287 |
| 11:45 ET | 527 | 3.55 |
| 12:00 ET | 300 | 3.555 |
| 12:07 ET | 5827 | 3.54 |
| 12:09 ET | 5800 | 3.58 |
| 12:12 ET | 200 | 3.58 |
| 12:14 ET | 4939 | 3.5601 |
| 12:21 ET | 100 | 3.59 |
| 12:23 ET | 300 | 3.58 |
| 12:25 ET | 100 | 3.59 |
| 12:27 ET | 100 | 3.59 |
| 12:36 ET | 100 | 3.57 |
| 12:39 ET | 116 | 3.58 |
| 12:52 ET | 200 | 3.58 |
| 01:03 ET | 200 | 3.59 |
| 01:15 ET | 658 | 3.5814 |
| 01:21 ET | 100 | 3.6 |
| 01:30 ET | 100 | 3.6 |
| 01:33 ET | 108 | 3.6 |
| 01:39 ET | 100 | 3.59 |
| 01:42 ET | 438 | 3.59 |
| 01:44 ET | 100 | 3.59 |
| 01:46 ET | 100 | 3.58 |
| 01:48 ET | 100 | 3.57 |
| 01:50 ET | 400 | 3.59 |
| 01:53 ET | 124 | 3.59 |
| 01:55 ET | 637 | 3.61 |
| 02:04 ET | 2778 | 3.61 |
| 02:20 ET | 396 | 3.62 |
| 02:29 ET | 110 | 3.6089 |
| 02:36 ET | 231 | 3.61 |
| 02:38 ET | 547 | 3.62 |
| 02:40 ET | 500 | 3.6 |
| 02:56 ET | 200 | 3.59 |
| 03:02 ET | 100 | 3.58 |
| 03:03 ET | 100 | 3.5801 |
| 03:09 ET | 300 | 3.57 |
| 03:12 ET | 300 | 3.57 |
| 03:16 ET | 100 | 3.57 |
| 03:18 ET | 100 | 3.56 |
| 03:20 ET | 642 | 3.57 |
| 03:25 ET | 100 | 3.56 |
| 03:32 ET | 100 | 3.56 |
| 03:38 ET | 229 | 3.57 |
| 03:39 ET | 390 | 3.5785 |
| 03:41 ET | 140 | 3.575 |
| 03:45 ET | 230 | 3.57 |
| 03:48 ET | 345 | 3.565 |
| 03:50 ET | 427 | 3.57 |
| 03:54 ET | 530 | 3.57 |
| 03:56 ET | 463 | 3.575 |
| 03:57 ET | 899 | 3.57 |
| 03:59 ET | 300 | 3.58 |
Apr 24, 2024
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, from 4:00PM ET on Wednesday Apr 24, 2024 by Dow Jones
4:00PM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 9, 2024
Apr 4, 2024
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:00PM ET on Thursday Apr 04, 2024 by Dow Jones
4:00PM ET on Thursday Apr 04, 2024 by Dow JonesDJ Mural Oncology Initiated at Overweight by Morgan Stanley, from 6:49AM ET on Thursday Apr 04, 2024 by Dow Jones
6:49AM ET on Thursday Apr 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mural Oncology PLC | 60.6M | -0.3x | --- |
OKYO Pharma Ltd | 49.6M | -0.1x | --- |
Maia Biotechnology Inc | 61.5M | -2.0x | --- |
Lantern Pharma Inc | 59.1M | -3.7x | --- |
Oncolytics Biotech Inc | 81.1M | -3.6x | --- |
RetinalGenix Technologies Inc | 62.2M | -29.1x | --- |
Company Information
Mural Oncology plc is a clinical-stage oncology company. The Company is leveraging its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. It leverages its expertise in cytokine biology, immune cell modulation and protein engineering capabilities to develop immunotherapies. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. Its portfolio of programs includes Nemvaleukin alfa (Nemvaleukin)-IL-2, IL-12, and IL-18. Nemvaleukin is an engineered interleukin-2 (IL-2) variant designed to harness the potent anti-cancer capabilities of high-dose rhIL-2 while minimizing toxicity by selectively activating cancer-fighting CD8 T cells and NK cells. The tumor-targeted split IL-12 program focuses on delivering the therapeutic potential of IL-12 by splitting it into inactive component.
Contact Information
- Headquarters
- 10 Earlsfort TerraceDUBLIN, Ireland D02 T380
- Phone
- ---
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $60.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 16.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-12.43 |
Book Value | $15.81 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
